3 Finished Dosage Generics Maker, Pharma Excipients and Nutrition Ingredients Maker and Vertically Integrated Garment Maker Stocks With a Strong Future Roadmap: Strides Pharma Science, Sudeep Pharma and KPR Mill
- November 2, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Strides Pharma Science, Sudeep Pharma and KPR Mill: ROE of 15.2% to 19.6% and FY22 to FY26 revenue CAGR of 8.4% to 17.6%. Prices as of 30 Oct 2026.
Quick Answer
The three generic drug, ingredient and garment stocks to watch are Strides Pharma Science, Sudeep Pharma and KPR Mill. Their return on equity ranges from 15.2% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 17.6%. Sudeep Pharma leads on both return on equity at 19.6% and revenue growth at 17.6% a year. Prices are based on the 30 October 2026 close, and this article is educational, not investment advice.
Generic drug, ingredient and garment stocks bring together companies with a visible plan for the years ahead. Strides Pharma Science, Sudeep Pharma and KPR Mill cover a finished dosage generics maker, a pharma excipients and nutrition ingredients maker and a vertically integrated garment maker.
This list covers three generic drug, ingredient and garment stocks with complete current figures: Strides Pharma Science, Sudeep Pharma and KPR Mill. Every figure comes from the latest reported financials and the 30 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Generic Drug, Ingredient and Garment Stocks?
Generic drug, ingredient and garment stocks are listed companies that make finished dosage generics for regulated markets, supply pharma excipients and nutritional ingredients, and spin yarn, knit fabric and stitch garments for global brands. Their earnings depend on export orders, approvals and input costs.
Generic Drug, Ingredient and Garment Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Strides Pharma Science | 1,068.8 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
| Sudeep Pharma | 1,068.3 | 11,352 | 61.8 | 35.1 | 19.6 | 0.17 |
| KPR Mill | 1,114.6 | 34,974 | 38.3 | 33.8 | 15.2 | 0.10 |
On valuation, Strides Pharma Science trades at a P/E below the industry P/E, while Sudeep Pharma and KPR Mill trade above it, which reflects the growth the market already expects. Readers comparing generic drug, ingredient and garment stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in generic drug, ingredient and garment stocks can use the coming numbers to test whether growth is holding.
Why Do Generic Drug, Ingredient and Garment Stocks Have a Strong Roadmap in India?
Generic drug, ingredient and garment stocks have a strong roadmap in India because steady generic demand, rising use of fortified food and global brands adding Indian sourcing keep widening the market for these export focused makers.
- Generic demand. Regulated markets buy more generics.
- Fortification. Nutrition ingredients see wider use.
- Sourcing shift. Global brands add Indian factories.
Why Strides Pharma Science Features Among These Generic Drug, Ingredient and Garment Stocks
Among the generic drug, ingredient and garment stocks on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Why Sudeep Pharma Features Among These Generic Drug, Ingredient and Garment Stocks
Among the export oriented shares on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.
Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%.
In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1.
Roadmap: Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
What to watch: Check capacity expansion progress and export revenue growth.
Why KPR Mill Features Among These Generic Drug, Ingredient and Garment Stocks
Among the three companies on this list, KPR Mill is a Coimbatore-based, vertically integrated apparel maker that spins yarn, knits fabric and stitches garments for global brands. It also runs sugar and ethanol operations and a growing retail business.
In the June 2026 quarter, revenue grew 9.3% year on year to Rs 1,970 crore, while net profit rose 21.6% to Rs 259 crore. Revenue rose from Rs 4,910 crore in FY22 to Rs 6,784 crore in FY26, a compound annual growth rate of 8.4%.
Net profit grew from Rs 815 crore in FY25 to Rs 866 crore in FY26, a rise of 6.3%. The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 34,974 crore. The stock trades at a P/E of 38.3, above the industry P/E of 33.8.
Roadmap: The company is adding garment and fabric capacity and deepening ties with large international apparel buyers. Its control over each step from yarn to garment supports delivery speed and quality.
What to watch: Track garment export orders, capacity additions and the progress of the retail business.
Strides Pharma Science vs Sudeep Pharma vs KPR Mill on Key Financials
The table below sets the three generic drug, ingredient and garment stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
| Sudeep Pharma | 350 | 671 | 17.6% | 174 | 26.0% |
| KPR Mill | 4,910 | 6,784 | 8.4% | 866 | 12.8% |
Sudeep Pharma posts the highest return on equity in this group at 19.6%. KPR Mill has the largest FY26 revenue at Rs 6,784 crore, and Sudeep Pharma shows the fastest revenue growth with a 17.6% compound annual rate. A useful habit with generic drug, ingredient and garment stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Strides Pharma Science | 1,128 | 1,270 | 12.6% |
| Sudeep Pharma | 130 | 164 | 25.9% |
| KPR Mill | 1,802 | 1,970 | 9.3% |
Key Risks to Check Before Investing in Generic Drug, Ingredient and Garment Stocks
Every theme carries risks that deserve a check before any decision. For these generic drug, ingredient and garment stocks, the main points are: Long-term export oriented shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Currency moves. Export earnings move with the rupee.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter generic drug, ingredient and garment stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Generic Drug, Ingredient and Garment Stocks
Generic drug, ingredient and garment stocks suit investors who prefer to study business strength before price moves. Strides Pharma Science, Sudeep Pharma and KPR Mill each have a clear plan to grow. Based on the 30 October 2026 close, Strides Pharma Science trades at Rs 1,068.8, Sudeep Pharma at Rs 1,068.3 and KPR Mill at Rs 1,114.6. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these generic drug, ingredient and garment stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track generic drug, ingredient and garment stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are generic drug, ingredient and garment stocks?
Ans. Generic drug, ingredient and garment stocks are listed companies that make finished dosage generics for regulated markets, supply pharma excipients and nutritional ingredients, and spin yarn, knit fabric and stitch garments for global brands. Their earnings depend on export orders, approvals and input costs. This list looks at three of them, Strides Pharma Science, Sudeep Pharma and KPR Mill, using reported FY22 to FY26 financials and the 30 October 2026 closing prices.
Which generic drug, ingredient and garment stocks are covered in this list?
Ans. This list covers Strides Pharma Science, Sudeep Pharma and KPR Mill. Based on the 30 October 2026 close, Strides Pharma Science traded at Rs 1,068.8, Sudeep Pharma at Rs 1,068.3 and KPR Mill at Rs 1,114.6. Their return on equity ranges from 15.2% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 17.6%.
Why do generic drug, ingredient and garment stocks have a strong future roadmap in India?
Ans. Generic drug, ingredient and garment stocks have a strong roadmap in India because steady generic demand, rising use of fortified food and global brands adding Indian sourcing keep widening the market for these export focused makers. The main drivers are as follows. Generic demand. Regulated markets buy more generics. Fortification. Nutrition ingredients see wider use. Sourcing shift. Global brands add Indian factories. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
How has Sudeep Pharma performed financially?
Ans. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
How has KPR Mill performed financially?
Ans. Revenue rose from Rs 4,910 crore in FY22 to Rs 6,784 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 815 crore in FY25 to Rs 866 crore in FY26, a rise of 6.3%. In the June 2026 quarter, revenue grew 9.3% year on year to Rs 1,970 crore, while net profit rose 21.6% to Rs 259 crore. The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 34,974 crore. The stock trades at a P/E of 38.3, above the industry P/E of 33.8. Looking ahead, the company is adding garment and fabric capacity and deepening ties with large international apparel buyers. Its control over each step from yarn to garment supports delivery speed and quality.
What risks should investors check before buying generic drug, ingredient and garment stocks?
Ans. Investors should check a few risks before buying generic drug, ingredient and garment stocks. Currency moves. Export earnings move with the rupee. Regulatory approvals. Plant inspections and approvals can affect supplies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of generic drug, ingredient and garment stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 30 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
